Keywords: bibw, patients, see, pr, german, drug, major

64% of BIBW 2992 patients see PR

Article | 18 May 2009

Print This

German drug major Boehringer Ingelheim will present new data on one of its lead oncology compounds, BIBW 2992, at the annual ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in